New approaches for the treatment of Alzheimer's disease

Paul V Fish; David Steadman; Elliott D Bayle; Paul Whiting

doi:10.1016/j.bmcl.2018.11.034

New approaches for the treatment of Alzheimer's disease

Bioorg Med Chem Lett. 2019 Jan 15;29(2):125-133. doi: 10.1016/j.bmcl.2018.11.034. Epub 2018 Nov 19.

Authors

Paul V Fish¹, David Steadman², Elliott D Bayle³, Paul Whiting⁴

Affiliations

¹ Alzheimer's Research UK UCL Drug Discovery Institute, The Cruciform Building, University College London, Gower Street, London WC1N 1E 6BT, UK; The Francis Crick Institute, 1 Midland Road, Kings Cross, London NW1 1AT, UK. Electronic address: p.fish@ucl.ac.uk.
² Alzheimer's Research UK UCL Drug Discovery Institute, The Cruciform Building, University College London, Gower Street, London WC1N 1E 6BT, UK.
³ Alzheimer's Research UK UCL Drug Discovery Institute, The Cruciform Building, University College London, Gower Street, London WC1N 1E 6BT, UK; The Francis Crick Institute, 1 Midland Road, Kings Cross, London NW1 1AT, UK.
⁴ Alzheimer's Research UK UCL Drug Discovery Institute, The Cruciform Building, University College London, Gower Street, London WC1N 1E 6BT, UK; The Dementia Research Institute, The Cruciform Building, University College London, Gower Street, London WC1N 1E 6BT, UK.

PMID: 30501965
DOI: 10.1016/j.bmcl.2018.11.034

Abstract

Alzheimer's disease (AD) is the most prevalent chronic neurodegenerative disease. Current approved therapies are symptomatic treatments having some effect on cognitive function. Therapies that target β-amyloid (Aβ) have been the focus of efforts to develop a disease modification treatment for AD but these approaches have failed to show any clinical benefit so far. Beyond the 'Aβ hypothesis', there are a number of newer approaches to treat AD with neuroinflammation emerging as a very active area of research based on risk gene analysis. This short review will summarize approved drug therapies, recent clinical trials and new approaches for the treatment of AD.

Keywords: Alzheimer’s disease; Disease modification; Drug discovery pipeline; Neurodegeneration; Neuroinflammation; Symptomatic treatments.

Publication types

Research Support, Non-U.S. Gov't
Review

MeSH terms

Alzheimer Disease / drug therapy*
Alzheimer Disease / metabolism
Amyloid beta-Peptides / antagonists & inhibitors*
Amyloid beta-Peptides / metabolism
Animals
Humans
Neuroprotective Agents / chemistry
Neuroprotective Agents / pharmacology*

Substances

Amyloid beta-Peptides
Neuroprotective Agents

Abstract

Publication types

MeSH terms

Substances

Grants and funding